Several cephalosporin antibiotics have been shown to induce defects in hemostasis (1, 2, 10, 12) . We therefore examined the effect of the new cephalosporin, cefamandole nafate (Mandol), on platelet function and coagulation. It has been shown that peak serum levels of 100 to 500 iLg/ ml are reached within 10 min when 2 g of cefamandole nafate are given intravenously over 10 min (3, 5) . Such levels prevail, however, only momentarily in intervals between repetitive treatments. Excretion is mainly by renal tubular secretion, and it is recommended that doses be adjusted in the presence of renal impainnent (13) .
In the following study, we evaluated the effect of cefamandole nafate on hemostatic function under the following circumstances: (i) in vivo, after a single 2-g intravenous (i.v.) infusion in six normal volunteers and after eight repetitive i.v. infusions (2 g every 6 h) in two patients; (ii) in vitro, after exposure of platelets and plasma from three normal volunteers and three uremic volunteers to a wide range of drug concentrations; and (iii) in vitro, after simultaneous exposure to high levels of both penicillin G and cefamandole nafate to test for possible synergism. Although application of in vitro data and findings after a single infusion to the usual clinical situation may be somewhat artificial, our results indicate no adverse effect of cefamandole nafate on coagulation. Alterations in hemostatic parameters were seen only in the presence of concentrations severalfold higher than those which might realistically be attained clinically.
Tio Blood samples were obtained from three normal and three uremic subjects that had not taken platelet-inhibiting drugs for at least 10 days for the detenmination of the one-stage prothrombin time (PT), activated partial thromboplastin time (APTT), reptilase time, thrombin time, fibrinolytic activity, fibrinogen titers, platelet factor 3 availability, and platelet aggregation. The blood urea nitrogen determinations and serum creatinine levels of the uremic patients ranged from 61 to 88 mg/dl and from 13.1 to 18.0 mg/dl, respectively. Values were determined in plasma samples and platelet-rich plasma (PRP) after 15 min of incubation with or without incremental concentrations of cefamandole nafate at 200, 400, 1,000, 2,000, 4,000, and 8,000 ,ug/ml.
In addition, PRP from three nornal subjects was incubated with inhibiting concentrations of either cefamandole nafate alone (1,000 ,ug/ml), penicillin G alone (2,000 iLg/ml), or both drugs simultaneously. They were aggregated with incremental doses of either ADP or collagen to determine the reversibility of inhibition.
All experiments were done in duplicate with simultaneous controls using volumes of normal saline equal to (Fig. 1) . In separate experiments, to test for possible synergistic effects, platelets were exposed to high doses of cefamandole nafate, penicillin G (known to inhibit aggregation), or both simultaneously. Each drug individually caused decreased maximum percent ADP-induced aggregation and collagen-induced aggregation characterized by lagphase prolongation with relative preservation of maximum percent aggregation (Fig. 2) . These changes were accentuated by incubation with both drugs simultaneously. By inducing aggregation with increased amounts of aggregating agents, it was possible to at least partially correct the altered aggregation patterns.
These data indicate the lack of hemostatic effect following brief in vivo exposure to cefamandole nafate. Also, while in vitro drug exposure may not be strictly comparable to clinical usage, our findings suggest that clotting function is preserved even in the presence of quite high drug concentrations. Alterations in clotting function (prolongation of PT and APTT and aggregation changes) were observed only in the presence of concentrations severalfold higher than expected peak serum levels. The mechanism of these changes is not revealed by our results. That thrombin times and fibrinolytic activity remained normal, however, mitigates against retarded fibrinogen-fibrin polymerization as a basis for PT and APTT prolongation, contrary to previous reports (2, 12) . The observed changes in ADP and collagen-induced aggregation patterns and reversal of these changes by induction with increased amounts of ADP suggests that at the nonphysiological concentrations of cefamandole nafate used, it may interfere with ADPplatelet receptor reactivity.
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